AOD-9604 research guide for Marlborough. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Researchers across Marlborough working with AOD-9604 operate within the global research peptide infrastructure: international suppliers, community reputation systems and analytical documentation standards that transcend geography. Research-grade AOD-9604 reaches Marlborough researchers through the same international supply chains that serve the broader research community — the barriers to access within Marlborough are mainly about knowledge rather than practical or legal for the majority of researchers in Marlborough. Marlborough's position in the research peptide supply chain is a destination for internationally supplied research peptides served by international vendors — the COA and storage requirements are no different from any other market globally. What follows covers the universal quality framework for AOD-9604 with observations specific to Marlborough import and shipping added for researchers in Marlborough.
The Science Behind AOD-9604
The oral bioavailability of MK-677 (Ibutamoren) distinguishes it from other compounds in the GHS class and has research design implications for Marlborough researchers. As an oral GHS, MK-677 avoids the technical requirements of injectable administration, making it more accessible for longer-term studies in non-specialized settings. Its half-life of approximately 24 hours produces a sustained GH elevation pattern, different from the acute pulsatile stimulation of injectable GHRPs. Marlborough researchers selecting between AOD-9604 options should consider whether acute pulsatile GH stimulation or sustained GH elevation is more relevant to their specific research question.
When evaluating AOD-9604 vendors for Marlborough shipping, three verification steps cover most of the relevant risk: verify peer standing in research communities, verify COA coverage for the actual batch you will receive, and verify confirmed shipping history to Marlborough. The COA verification step that Marlborough researchers sometimes omit is checking that the certificate batch reference matches the actual vial you receive — a COA is only meaningful when it is traceable to your particular vial. Express shipping options from most major vendors shorten delivery to roughly a week — customs processing is the main factor affecting delivery consistency, typically accounting for 2-5 extra days in most cases. For Marlborough researchers making their first AOD-9604 purchase: the combination of peer reputation checking, analytical verification, and a modest initial quantity is consistently the safest and most effective approach.
Safe Research Practices for AOD-9604
AOD-9604 handling safety for Marlborough researchers: store lyophilised powder at −20°C, reconstitute with bacteriostatic water only, maintain refrigeration during reconstituted use, and dispose of sharps in line with applicable Marlborough disposal rules. Vendor-provided endotoxin testing is a prerequisite for injectable research use — verify this is present in the batch-matched COA before any injectable application. For institutional researchers in Marlborough: research approval and ethics processes apply to AOD-9604 research just as they do to other research compounds — check with your institution before beginning formal protocols.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
